Geron Corp (GERN)
NASDAQ · Manufacturing · Pharmaceutical preparations
GERN price, last 12 months
Key stats
- Previous close
- $1.26
- Open
- $1.26
- Day range
- $1.24 – $1.27
- 52-week range
- $1.04 – $2.01
- Volume
- 10.3M
- Avg volume (20 days)
- 10.9M
- Market cap
- $809.5M
Performance
Technicals and fundamentals
About Geron Corp
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $809.5M